A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression

Table 1 Candidate proteins used for validation and details

Candidate Proteins	Accession Number	iTRAQ		IHC (PsPD vs N-GBM)	WB Quantitative Analysis
Candidate Proteins	Accession Number	FC (PsPD vs N-GBM)	P value	IHC (PsPD vs N-GBM)	PsPD vs N-GBM (MS)	PsPD vs N-GBM ^#	PsPD vs R-GBM ^#
HNRNPK	P61978	0.34	**	down-regulation	0.82	0.26	0.14*
ELAVL1	B4DVB8	0.23	**	down-regulation	0.46*	0.33	0.21*
FBLN1	P23142	2.74	**	up-regulation	1.19	1.63*	1.43
CDH2	P19022	0.29	0.05	down-regulation	0.1*	0.35	0.4
CALU	O43852	0.33	0.15	down-regulation	No Validation	No Validation	No Validation
FGB	P02675	16.06	**	up-regulation	No Validation	No Validation	No Validation

Note: The 1st column refers to the candidate proteins used for validation; the 2nd column refers to the corresponding accession number of these candidate proteins; the 3rd column refers to the results of iTRAQ labeled quantitative analysis, FC, fold change, **p < 0.01; The 4th column refers to the differential expression levels of these candidate proteins in the immunohistochemistry (IHC) analysis; The 5th column refers to the results of the western blot validation of the 4 candidate proteins, ELAVL1, HNRNPK, CDH2 and FBLN1, ^#indicates the results in additional samples, *p < 0.05.

ISSN: 1477-5956